Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales

Eli Lilly's $7.8 billion acquisition of Centessa Pharmaceuticals has cleared a critical regulatory hurdle with UK court approval, eliminating a material overhang for both firms. The deal structure—$38 per share cash plus up to $9 per share in contingent value rights tied to clinical milestones—reflects confidence in Centessa's neurological pipeline while managing execution risk through performance-based earnout provisions.

For LLY, this acquisition accelerates its portfolio diversification in the high-value neurology space, particularly in excessive daytime sleepiness treatment. The $7.8 billion price tag is material but manageable for Lilly's scale; the deal signals aggressive oncology and neuro-specialty positioning amid competitive pressures in pharma innovation. Court approval removes regulatory uncertainty and de-risks deal closure.

The transaction's approval trajectory supports investor confidence in M&A completion risk premiums in healthcare consolidation. Centessa shareholders gain defined downside ($38 cash floor) with CVR upside tied to clinical validation, a structure increasingly common in biotech acquisitions where target pipelines carry development risk rather than near-term revenue.

Sector implication: Pharma and biotech consolidation activity signals strong conviction in specialized therapeutic areas and IP value amid patent cliff pressures. The deal underscores large-cap pharma's capital deployment strategy favoring clinical-stage acquisitions over organic R&D in competitive neurology markets.